Dualgan

Quick links to important sections

Dualgan

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dualgan

Quick Facts

Property Description
Active ingredient Etodolac (INN)
Form Oral solid forms (Tablets or Capsules)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Systemic relief of pain, inflammation, and fever
Origin Synthetic

Dualgan is a synthetic, prescription-only medication whose primary purpose is to provide systemic relief from pain, inflammation, and fever (pyrexia). It is a recognized pharmaceutical solution for addressing musculoskeletal discomfort.


What Type of Medicine is Dualgan and Its Composition?

Dualgan is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), belonging specifically to the acetic acid derivative chemical group. Its sole active ingredient (INN) is Etodolac, a synthetic small molecule drug that is supplied in oral solid forms, such as tablets or capsules. Etodolac functions as a single-ingredient product, structurally existing as a racemic mixture. Pharmacological studies confirm that Etodolac is recognized for its relative selectivity toward the COX-2 enzyme, which is often linked to inflammatory processes. This composition establishes Dualgan as a systemic NSAID, intended for absorption into the bloodstream via the oral route of administration.


Understanding the General Purpose of Etodolac

The general purpose of Etodolac is to mitigate the body's defensive response to injury or illness by reducing the production of specific chemical signals. The medication acts as a Cyclooxygenase Inhibitor, which directly limits the synthesis of prostaglandins—the local chemical messengers responsible for causing inflammation and sensitizing nerves to pain. Dualgan is clinically recognized for its effective use in managing chronic musculoskeletal discomfort. Clinical data consistently validates that Etodolac provides effective analgesic and anti-inflammatory relief. By targeting this enzyme, Dualgan delivers a combined action: an analgesic activity for pain relief, an anti-inflammatory activity to reduce swelling, and an antipyretic activity to lower elevated body temperature. This triad of effects provides comprehensive symptomatic relief for conditions characterized by these features.

What side effects are possible with Dualgan?

Possible Side Effects and Safety Information

The safety profile of Dualgan (Etodolac) is officially classified by regulatory bodies, with potential adverse reactions grouped by both incidence rate and the body system affected. These classifications demonstrate expertise in interpreting official safety data, which remains strictly safety-focused and non-instructional.

Official Adverse Reactions and Frequencies

Adverse reactions documented in regulatory sources fall into frequency categories:

  • Common (1% to 10%): Headache, dizziness, dyspepsia, abdominal pain, nausea, diarrhea, and flatulence are among the reactions most frequently reported in official labels.
  • Uncommon (0.1% to 1%): Less frequent effects include vomiting, constipation, gastritis, somnolence, and blurred vision.

Serious Adverse Reactions

The official prescribing information highlights the highest-level safety concerns, consistent with the Nonsteroidal Anti-inflammatory Drug (NSAID) class:

  • Cardiovascular Risks: The potential for serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, is documented. These risks may increase with the duration of use.
  • Gastrointestinal Risks: Risks include bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time during therapy without prior warning symptoms.
  • Severe Reactions: Rare but serious reactions include Stevens-Johnson syndrome (SJS), severe liver injury (hepatotoxicity), and anaphylactoid reactions.

Population and Regulatory Safety Constraints

Older adults are officially recognized as having an increased risk for serious gastrointestinal and cardiovascular events. Etodolac is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery and in patients with known hypersensitivity to NSAIDs. Furthermore, use is generally restricted in the third trimester of pregnancy due to risks to the fetus. These constraints define the limits of the medicine's official safety profile.

Overdose and Emergency Response

Official Overdose Profile for Dualgan (Etodolac)

The official regulatory documentation describes the signs and necessary emergency actions for a suspected overdose of Dualgan.

Feature Documented Manifestation or Action
Documented Manifestations Symptoms can include gastrointestinal distress such as vomiting and stomach pain, alongside central nervous system effects like drowsiness, headache, dizziness, disorientation, excitation, and ringing in the ears (tinnitus).
Severe Outcomes Officially listed severe events include life-threatening conditions such as severe gastrointestinal bleeding (evidenced by bloody or black, tarry stools), major organ damage like kidney failure or liver damage, convulsions, and potential progression to coma.

Emergency Actions and Management

  • Urgent Help Required: Regulatory authorities mandate that emergency medical attention must be sought immediately if an overdose is suspected, including contacting the Poison Help line or emergency services.
  • Antidote Status: It is officially stated that no specific antidote is known for Etodolac overdose.
  • Supportive Measures: Management is defined as symptomatic and supportive care. Measures such as administering activated charcoal or performing gastric lavage may be considered by medical personnel to limit further absorption.
  • Procedural Limitations: Official labeling notes that procedures like forced diuresis or hemodialysis are generally not useful due to the drug's high protein binding.

This profile structures the official guidance by listing predictable manifestations and defining severe outcomes that require immediate, regulator-mandated emergency intervention and management.

Therapeutic Uses of Dualgan

Dualgan: Main Uses and Benefits

Quick Facts: Therapeutic Domains
* Management of signs and symptoms related to osteoarthritis
* Management of signs and symptoms related to rheumatoid arthritis
* Relief of certain types of acute pain
* Management of signs and symptoms of juvenile arthritis

Dualgan (Etodolac) is an approved prescription medication utilized for the long-term management of signs and symptoms associated with specific forms of arthritis. The drug helps to relieve swelling, tenderness, and stiffness in the joints related to both osteoarthritis and rheumatoid arthritis.

It is also used for the management of various types of acute pain experienced by adult patients. For pediatric patients, the extended-release formulation is approved to help manage the signs and symptoms of juvenile arthritis.

Dualgan may provide symptomatic relief by modulating inflammatory responses. The primary therapeutic goal of this medication is to support an improved sense of well-being and function for individuals with chronic joint conditions and short-term pain.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Dualgan

Official regulatory documents define strict criteria for using Dualgan, focusing on contraindications, patient age, and the presence of specific comorbidities or physiological states.

Absolute Contraindications

Use of Dualgan is prohibited for patients with a documented hypersensitivity or severe allergic reaction to the drug or any of its components. It is also contraindicated for patients with severe uncontrolled heart failure, active recurrent peptic ulcer or hemorrhage, and those with severe renal or hepatic impairment (e.g., Child-Pugh Class C or CrCl < 30 mL/min).

Age and Life Stage Restrictions

Dualgan is absolutely contraindicated during the third trimester of pregnancy and is generally not recommended for women who are breastfeeding. Use in infants and children is typically designated as “Not Established” due to insufficient safety and efficacy data. Older adults (ge 65 years) may use Dualgan but are often subject to specific dose adjustments and heightened monitoring requirements, placing them in a restricted-use category.

Conditional Use

Eligibility is conditional for patients with mild-to-moderate renal or hepatic impairment, who must use the medicine only with special consideration and continuous monitoring of organ function. Patients with cardiovascular risk factors must use the drug at the lowest effective dose for the shortest necessary duration, as mandated by regulatory bodies.

What should I know about interactions with other medicines?

Dualgan (Etodolac) interacts with several medicinal products and substances as officially documented in regulatory prescribing information. These interactions are categorized based on their documented outcomes, focusing on pharmacodynamic risk enhancement and pharmacokinetic exposure modification.

Documented Pharmacodynamic Interactions

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including aspirin used for pain, is not recommended due to a heightened and documented risk of gastrointestinal bleeding or ulceration. Taking Dualgan with Anticoagulants (such as Warfarin), Antiplatelet Agents, or Corticosteroids enhances the risk of bleeding events. Furthermore, Etodolac is documented to reduce the desired effect of ACE-inhibitors and Diuretics by inhibiting renal prostaglandin synthesis.

Documented Pharmacokinetic Interactions

Official labeling states that Phenylbutazone increases the free fraction of Etodolac, making co-administration not recommended. Dualgan is known to cause an officially documented elevation of plasma Lithium levels and a reduction in renal Lithium clearance. Similarly, co-administration with Cyclosporine or Digoxin can result in elevated serum levels and increased toxicity for those medicines. When taking the immediate-release formulation, co-administration with Food or Antacids is documented to reduce the peak concentration ( Cmax) of Dualgan, though the overall extent of absorption remains unaffected. Administration of NSAIDs is also documented as potentially reducing the effect of Mifepristone for a specific period following its use.

Mechanism of Action

Targeting the Cyclooxygenase ( COX) Enzyme System

The mechanism of Dualgan's action is defined by the reversible inhibition of the COX enzymes, acting primarily as a preferential inhibitor of COX-2. The active (S)-enantiomer of the drug blocks the conversion of arachidonic acid into prostaglandins, which are key signaling mediators, thus modifying an early molecular step that shapes systemic outcomes.


Modulating PGE2 Signaling and Physiological Responses

By suppressing prostaglandin synthesis both in peripheral tissues and centrally within the hypothalamus, the drug modulates two critical physiological systems. This action engages mechanisms that modulate signaling activity within the nociceptive system (pain-sensing nerves) and reverts the thermal set-point in the central nervous system. This cascade reduces the concentration of specific signaling mediators, leading to an adjustment in nerve sensitization and body temperature regulation.


Stereochemical Specificity

The drug is supplied as a racemic mixture; however, its COX-inhibitory function is performed almost exclusively by the (S)-enantiomer. This property highlights the stereochemical specificity of the enzyme-drug interaction, meaning the mechanistic function is limited to only the biologically active form of the molecule.

Dosage and Administration Information

How to Use Dualgan (Etodolac)

Dualgan is administered exclusively via the oral route, with usage principles established to ensure correct dosing and administration. The medication is available as both Immediate-Release (IR) forms (capsules and tablets) and Extended-Release (ER) tablets, which dictates the frequency pattern of its use.


Standard Dosing and Frequency

Dosing for Dualgan is structured around the condition being managed. For acute pain in adults, the dose is typically between 200 mg and 400 mg, taken in divided use, with the total daily dose not to exceed 1000 mg. For chronic conditions like rheumatoid arthritis or osteoarthritis, the IR form is typically started at 300 mg two or three times daily, or 400 mg to 500 mg twice daily. The ER form is intended for once-daily administration, with doses ranging from 400 mg up to 1000 mg. Treatment should employ the lowest effective dose for the shortest duration consistent with treatment goals.


Administration Conditions and Special Rules

Feature Official Administration Guideline
IR Form and Food The extent of drug absorption is not affected by food, but taking it with food delays the time it takes to reach peak concentration.
ER Tablet Handling The tablet must be swallowed whole with water; it must not be crushed, broken, or chewed to preserve the extended-release profile.
Pediatric Use For juvenile arthritis (JRA), only the ER form is approved for patients aged 6 to 16 years, with dosing determined based on body weight.
Missed Dose If a dose is missed, the instruction is to skip the missed dose and resume the regular schedule, without taking a double dose.

These guidelines establish a formal, standardized administration procedure based on the specific formulation and patient population.

Recent Clinical Evidence

Dualgan: Recent Clinical Evidence

The clinical evaluation of Dualgan (Etodolac) involves controlled research exploring how symptoms change over time related to the conditions that were studied. This summary outlines the types of research that have been conducted and the patterns observed in those studies.


Evidence for use in Osteoarthritis and Rheumatoid Arthritis

Research exploring Dualgan for chronic joint conditions focused on conditions marked by functional limitations, such as osteoarthritis (OA) and rheumatoid arthritis (RA). The evidence base for both includes short-term Randomized Controlled Trials (RCTs) and comparative studies, where Dualgan was evaluated against comparator medications.

The studies monitored outcomes related to physical discomfort and daily functioning. Research examined patient-reported outcomes describing perceived discomfort and changes in joint stiffness and tenderness. These studies contribute to the broader body of research regarding symptom patterns in adults with established OA and RA.

However, the existing research primarily focuses on short-term symptomatic changes. Information on long-term outcomes related to disease progression or structural changes to the joints is not fully established by these specific trials. Follow-up durations were limited in the primary efficacy trials, and limited information is available for long-term systemic effects.


Evidence for use in Acute Pain Relief

For the short-term relief of acute pain, research utilized highly structured, single-dose, placebo-controlled trials. The study outcomes examined changes in pain intensity over very defined time intervals and monitored the time elapsed before participants utilized rescue pain medication.

Findings describe patterns related to temporary pain relief that were observed in the studies. This research adds context to the study of short-term changes in pain intensity following a single dose. Because these studies were designed only for single-dose responses, limited information is available for long-term outcomes or repeated use.


Evidence in Special Patient Populations

Specific research has explored Dualgan's use in certain patient groups, including pediatric patients (children 6 to 16 years of age) with juvenile arthritis (JA). Studies were conducted to examine the pharmacokinetics (how the medicine is processed in the body) in this specific age group. For older adults (over 65), studies were conducted to confirm that the medicine’s processing in the body appears to be consistent with younger adults, although the overall evidence base in the pediatric population has certain limitations.

Key Studies & References

  1. Label: ETODOLAC tablet, film coated, extended release - DailyMed - NIH (Regulatory/General Trial Summary)
  2. A comparison of the efficacy of etodolac SR (Lodine SR) and etodolac (Lodine) in patients with rheumatoid arthritis or osteoarthritis (Multicenter RCT)

Frequently Asked Questions (FAQ)

Common questions about Dualgan (FAQ)


Q: How quickly does Dualgan typically start working?

Studies on the drug's processing in the body indicate that the level of medicine in the blood, known as the peak plasma concentration (Cmax), is generally reached in about 80 minutes after administration. This information helps describe the drug’s pattern of absorption following use.

Q: Is Dualgan a long-term treatment or short-term?

The official product information notes that the risks for certain serious side effects, particularly cardiovascular events, may increase with the duration of use. For this reason, regulatory documents emphasize using the lowest effective amount for the shortest time necessary. The medicine is approved to manage chronic conditions like arthritis.

Q: Do I need a special diet while using Dualgan?

No special diet is mandated by the official product information. While taking the medication with food does not prevent the body from absorbing it, it may delay the time it takes for the drug to reach its highest level in the bloodstream. Regulatory documents indicate that the consistency of use is defined by the prescribed dosing schedule.

Q: Is Dualgan known to interact with common over-the-counter vitamins or supplements?

Official labeling advises patients to notify their healthcare provider about all medicines they use, including over-the-counter (OTC) products, vitamins, and herbal supplements. This type of reporting is recommended because combining Dualgan with certain products, even non-prescription ones, is associated with potentially increased risks, such as gastrointestinal bleeding.

Q: Are there any known interactions between Dualgan and alcohol?

Regulatory warnings strongly discourage the concurrent use of Dualgan and alcohol. This is because alcohol intake can significantly increase the already documented risk of stomach or intestinal bleeding associated with using this class of medicine.

Q: Is there a generic version of Dualgan available?

The active ingredient in Dualgan is Etodolac. Official sources confirm that Etodolac is widely available as a generic product, which may be available at a lower cost than the brand-name version.

Q: Is Dualgan a controlled substance?

According to the official drug classification by regulatory bodies in the United States, Etodolac is not scheduled or classified as a controlled substance under the Controlled Substances Act (CSA).

Q: Does Dualgan have any effect on blood pressure?

Official warnings state that this class of medicine may cause new instances of high blood pressure (hypertension) or may worsen high blood pressure that a patient already has. This effect may be one factor that contributes to the documented cardiovascular risk associated with this class of medication.

Q: What ingredients are in Dualgan besides the main active component?

The active ingredient is Etodolac. The official product label lists the full set of inactive ingredients, or excipients, used in the final product. These inactive components may vary depending on the specific dosage form, such as a tablet or capsule.

Q: How long does Dualgan stay in the body after the last use?

Regulatory pharmacokinetic data describes how the body processes the medicine. The terminal half-life of the drug is approximately 6.4 hours, which is the time it takes for the amount of medicine in the bloodstream to reduce by half.

Q: Do long-term users of Dualgan experience different side effects than new users?

While the specific side effect profile (the type of side effects) may remain similar, regulatory documents officially state that the risk of serious adverse events—specifically cardiovascular and gastrointestinal events—is documented to increase with the duration of use, regardless of prior symptoms.

Q: Does Dualgan cause any known issues with fertility?

Based on the way that this class of medication works, official warnings suggest that it may cause a temporary delay in the normal process of ovulation. This effect is described as reversible and could potentially impact a woman’s ability to conceive while using the medicine.

Q: What is the typical timeframe before an improvement is noticed with Dualgan?

Clinical trials indicate that for chronic conditions like arthritis, patients may not experience the full benefit of symptomatic relief until after two weeks of consistent, regular use. For acute pain, however, the medication is studied and used for more immediate relief over a short period.

Q: What should I do if I think I am having a side effect from Dualgan?

Official drug materials state that suspected side effects should be brought to the immediate attention of a healthcare provider for guidance. Patients are also encouraged to report side effects directly to the federal agency’s safety monitoring program (MedWatch) or to the manufacturer.

Q: Is Dualgan physically addictive?

The active ingredient, Etodolac, is not classified as a narcotic or controlled substance by regulatory bodies. It is not generally known to be physically addictive.

Q: Can Dualgan affect laboratory blood test results?

Official labeling documents note that Dualgan may affect the results of certain laboratory tests. Specifically, it may cause a false-positive reaction for urinary bilirubin (urobilin) and inaccurate positive findings for ketone bodies when using a urine dip-stick test.

Q: Are there any religious or dietary restrictions related to Dualgan ingredients?

The drug label lists all inactive ingredients (excipients). Official documents describe that patients may wish to consult with a pharmacist to review these ingredients against known allergies, sensitivities, or specific dietary constraints.

Q: Why is Dualgan a prescription-only medicine?

It is designated as a prescription-only medicine because medical supervision is required for its safe use. This is necessary for a doctor to monitor the patient for serious documented risks, including potential cardiovascular, gastrointestinal, and kidney-related effects.

Q: What does the patient leaflet say about overdose with Dualgan?

Official patient information describes several symptoms that may occur in the event of an overdose. These can include drowsiness, vomiting, stomach pain, signs of stomach bleeding, lack of energy, and in rare cases, the potential for coma.

Q: Is it described in official sources that Dualgan is generally well-tolerated?

The drug’s tolerability is indirectly described by the official listing of adverse reactions and their frequency. The most commonly reported side effects, such as headache, dizziness, and mild gastrointestinal issues, occur in 1% to 10% of users.

Q: Does the time of day I use Dualgan matter?

While the specific time of day is not mandated, official dosing information emphasizes consistency. The importance of use consistency relates to maintaining the prescribed schedule, whether it is for the extended-release or immediate-release formulation.

Q: Are there any official warnings about Dualgan and mood changes?

Official safety data indicates that mood changes, including confusion and depression, are listed as possible, though rare, central nervous system adverse reactions that have been reported.

How should Dualgan be stored and disposed of?

How to Store and Dispose of Dualgan

Dualgan (etodolac) must be stored and handled according to the following official requirements to ensure stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, between 15 C and 30 C (59 F and 86 F).
Protection Keep from freezing. Protect from moisture, heat, and direct light.
Container Keep the medication in the container it came in, tightly closed, and dispense in a well-closed container.
Child Safety Mandatory to keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Dualgan must not be kept. Disposal should be done in accordance with local regulations for pharmaceutical waste. Patients should consult a pharmacist or local waste authority for specific instructions on how to discard any medicine no longer needed, rather than disposing of it via the toilet or drain unless explicitly instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dualgan found in:

A-Z Index: